BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, January 8, 2026
See today's BioWorld Asia
Home
» Vitalli Bio launches with $477M licensing deal with Daewoong for phase I-ready autoimmune disease candidate
To read the full story,
subscribe
or
sign in
.
Vitalli Bio launches with $477M licensing deal with Daewoong for phase I-ready autoimmune disease candidate
May 2, 2023
By
Tamra Sami
Daewoong Pharmaceutical Co. Ltd. has out-licensed its phase I-ready autoimmune disease candidate, DWP-213388, to new spinout company Vitalli Bio in a deal worth up to $477 million.
BioWorld Asia
Deals and M&A
Immune
Asia-Pacific
